© 2020 MJH Life Sciences and OncLive. All rights reserved.
By: Henry M. Kuerer, MD, PhD, FACS
The management of ductal carcinoma in situ is one of the most controversial areas in breast cancer management.
By: Jeffrey Zweig, MD
With several new promising options, Jeffrey Zweig, MD, and Heather Wakelee, MD attempt to better answer the question of which ALK tyrosine kinase inhibitor (TKI) should be favored upfront.